2023
Clinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation
Hurley N, Dhruva S, Desai N, Ross J, Ngufor C, Masoudi F, Krumholz H, Mortazavi B. Clinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation. ACM Transactions On Computing For Healthcare 2023, 4: 1-18. PMID: 37908872, PMCID: PMC10613929, DOI: 10.1145/3616021.Peer-Reviewed Original Research
2020
1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
REIFSNIDER O, PIMPLE P, STARGARDTER M, BRAND S, DESAI N, SHETTY S. 1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. Diabetes 2020, 69 DOI: 10.2337/db20-1158-p.Peer-Reviewed Original ResearchBoehringer Ingelheim PharmaceuticalsUse of empagliflozinT2D patientsCardiovascular diseaseAdverse eventsUnited Kingdom Prospective Diabetes Study (UKPDS) risk equationsGLP-1 receptor agonistsT2D-related complicationsSecond-line therapyType 2 diabetesClinical trial resultsTreatment-induced changesBackground metforminCVD subgroupsCV deathRenal outcomesHazard ratioClinical outcomesSGLT2 inhibitorsCVS CaremarkMyocardial infarctionReceptor agonistSpouse/partnerImproved outcomesDrug classes